试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Substipharm
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-507630-25-00Ferring Pharmaceuticals A/S600
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507486-26-00Bayer Consumer Care AG135
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200
进行中（未招募）
1 期
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104Prostate cancerCTIS2023-506435-15-00Bayer Consumer Care AG60